Auris Medical Holding AG Company Profile (NASDAQ:EARS)

About Auris Medical Holding AG (NASDAQ:EARS)

Auris Medical Holding AG logoAuris Medical Holding AG is a holding and clinical-stage biopharmaceutical company focused on the development of products for the treatment of inner ear disorders. Its advanced product candidate, AM-101, is in Phase III clinical development for acute inner ear tinnitus under a special protocol assessment (SPA) from the United States Food and Drug Administration. Its second product candidate, AM-111, is being developed for the treatment of acute sensorineural hearing loss (ASNHL). It intends to conduct over two pivotal Phase III trials in the treatment of idiopathic sudden SNHL (ISSNHL), titled Acute Inner Ear Hearing Loss (HEALOS) and Acute Sudden Sensorineural Hearing Loss Treatment (ASSENT). AM-111 received orphan drug designation for the treatment of ASNHL from the United States Food and Drug Administration, and the European Union agency. It intends to conduct a Phase II trial in the treatment of surgery-induced hearing loss (REACH).

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: N/A
  • Symbol: NASDAQ:EARS
  • CUSIP: N/A
  • Web: www.aurismedical.com
Capitalization:
  • Market Cap: $22.92 million
  • Outstanding Shares: 34,329,000
Average Prices:
  • 50 Day Moving Avg: $0.74
  • 200 Day Moving Avg: $0.99
  • 52 Week Range: $0.62 - $5.45
P/E:
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -1.04
  • P/E Growth: 0.0000
Sales & Book Value:
  • Annual Revenue: N/A
  • Price / Sales: N/A
  • Book Value: $0.42 per share
  • Price / Book: 1.61
Profitability:
  • EBIDTA: ($30,320,000.00)
  • Return on Equity: -96.60%
  • Return on Assets: -70.59%
Debt:
  • Debt-to-Equity Ratio: 0.55%
  • Current Ratio: 4.75%
  • Quick Ratio: 4.75%
Misc:
  • Average Volume: 518,958 shs.
  • Beta: 1.13
  • Short Ratio: 1.38
 

Frequently Asked Questions for Auris Medical Holding AG (NASDAQ:EARS)

What is Auris Medical Holding AG's stock symbol?

Auris Medical Holding AG trades on the NASDAQ under the ticker symbol "EARS."

How were Auris Medical Holding AG's earnings last quarter?

Auris Medical Holding AG (NASDAQ:EARS) posted its earnings results on Thursday, May, 11th. The company reported ($0.22) earnings per share for the quarter, missing the Thomson Reuters' consensus estimate of ($0.14) by $0.08. View Auris Medical Holding AG's Earnings History.

Where is Auris Medical Holding AG's stock going? Where will Auris Medical Holding AG's stock price be in 2017?

5 equities research analysts have issued 1 year target prices for Auris Medical Holding AG's shares. Their predictions range from $4.00 to $12.00. On average, they anticipate Auris Medical Holding AG's share price to reach $6.83 in the next year. View Analyst Ratings for Auris Medical Holding AG.

What are analysts saying about Auris Medical Holding AG stock?

Here are some recent quotes from research analysts about Auris Medical Holding AG stock:

  • 1. Needham & Company LLC analysts commented, "EARS reported 4Q16 financials and update its three ongoing development programs. The next key data catalyst for EARS will be ph 3 HEALOS results for AM-111 (hearing loss) in 3Q17. The study, which should complete enrollment in 2Q17, is the first of two AM-111 pivotal studies in hearing loss. The Keyzilen program will first report results from the open-label studies (AMPACT-1 and 2) in 2Q17 while the recently modified TACCT3 study is on track to have top-line results in 1Q18. EARS plans to evaluate AM-125 (Meniere's disease/vertigo) in an additional ph 1 trial (initiating in 2H17) prior to discussing a regulatory pathway with regulatory authorities. The current EARS market valuation appears to place minimal to no value on any of the ongoing clinical programs.We maintain our Buy rating and adjust our $PT to $4 (from $5)." (3/14/2017)
  • 2. According to Zacks Investment Research, "Auris Medical Holding AG is a biopharmaceutical company. It focuses on developing therapies for the treatment of hearing loss and tinnitus. The Company has two projects in advanced clinical development: AM-101 for the treatment of acute inner ear tinnitus and AM-111 for the treatment of acute inner ear hearing loss. Auris Medical Holding AG is headquartered in Zug, Switzerland. " (1/10/2017)

Are investors shorting Auris Medical Holding AG?

Auris Medical Holding AG saw a increase in short interest in April. As of April 28th, there was short interest totalling 1,075,288 shares, an increase of 15.4% from the April 13th total of 932,128 shares. Based on an average trading volume of 174,449 shares, the short-interest ratio is currently 6.2 days.

Who are some of Auris Medical Holding AG's key competitors?

Who owns Auris Medical Holding AG stock?

Auris Medical Holding AG's stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include SOFINNOVA VENTURE PARTNERS VIII, L.P. (20.20%), Sofinnova Management VIII L.L.C. (22.77%), Bellevue Group AG (6.32%), Tekla Capital Management LLC (2.26%), Perceptive Advisors LLC (1.17%) and Morgan Stanley (0.44%). View Institutional Ownership Trends for Auris Medical Holding AG.

Who bought Auris Medical Holding AG stock? Who is buying Auris Medical Holding AG stock?

Auris Medical Holding AG's stock was purchased by a variety of institutional investors in the last quarter, including Sofinnova Management VIII L.L.C., Perceptive Advisors LLC, Morgan Stanley and Sabby Management LLC. View Insider Buying and Selling for Auris Medical Holding AG.

How do I buy Auris Medical Holding AG stock?

Shares of Auris Medical Holding AG can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How much does a share of Auris Medical Holding AG stock cost?

One share of Auris Medical Holding AG stock can currently be purchased for approximately $0.67.

Analyst Ratings

Consensus Ratings for Auris Medical Holding AG (NASDAQ:EARS) (?)
Ratings Breakdown: 1 Hold Rating, 4 Buy Ratings
Consensus Rating:Buy (Score: 2.80)
Consensus Price Target: $6.83 (923.41% upside)

Analysts' Ratings History for Auris Medical Holding AG (NASDAQ:EARS)
Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
4/13/2017Roth CapitalInitiated CoverageBuy -> Buy$4.50MediumView Rating Details
3/14/2017Needham & Company LLCLower Price TargetBuy$5.00 -> $4.00HighView Rating Details
11/11/2016JMP SecuritiesReiterated RatingHoldN/AView Rating Details
6/15/2016Leerink SwannReiterated RatingBuy$12.00N/AView Rating Details
6/10/2016Jefferies Group LLCReiterated RatingBuyN/AView Rating Details
(Data available from 5/24/2015 forward)

Earnings

Earnings History for Auris Medical Holding AG (NASDAQ:EARS)
Earnings by Quarter for Auris Medical Holding AG (NASDAQ:EARS)
Earnings History by Quarter for Auris Medical Holding AG (NASDAQ:EARS)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/11/20173/31/2017($0.14)($0.22)ViewN/AView Earnings Details
3/14/201712/31/2016($0.29)($0.16)ViewN/AView Earnings Details
11/10/2016Q316($0.28)($0.23)ViewListenView Earnings Details
5/11/2016Q116($0.23)($0.26)ViewListenView Earnings Details
3/14/2016Q415($0.29)($0.16)ViewListenView Earnings Details
11/12/2015Q315($0.28)($0.16)ViewListenView Earnings Details
8/19/2015Q215($0.23)($0.36)ViewListenView Earnings Details
5/28/2015Q115($0.22)($0.29)ViewListenView Earnings Details
3/19/2015Q4($0.23)($0.17)ViewListenView Earnings Details
12/3/2014Q3($0.24)($0.14)ViewN/AView Earnings Details
9/15/2014Q2 2014($0.34)($0.29)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Auris Medical Holding AG (NASDAQ:EARS)
Current Year EPS Consensus Estimate: $-0.5700 EPS
Next Year EPS Consensus Estimate: $-0.6400 EPS

Dividends

Dividend History for Auris Medical Holding AG (NASDAQ:EARS)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Auris Medical Holding AG (NASDAQ:EARS)
No insider trades for this company have been tracked by MarketBeat.com

Headlines

Headline Trends for Auris Medical Holding AG (NASDAQ:EARS)
Latest Headlines for Auris Medical Holding AG (NASDAQ:EARS)
Source:
DateHeadline
bizjournals.com logoHow These Biotech Stocks are Faring? -- Auris Medical, Eleven Biotherapeutics, Inotek Pharma, and Marinus Pharma
www.bizjournals.com - May 18 at 10:34 AM
americanbankingnews.com logoAuris Medical Holding AG (EARS) Sees Large Increase in Short Interest
www.americanbankingnews.com - May 16 at 7:20 AM
americanbankingnews.com logoAuris Medical Holding AG (EARS) Issues Quarterly Earnings Results
www.americanbankingnews.com - May 12 at 11:48 AM
reuters.com logoBRIEF-Auris Medical reports Q1 loss per share chf 0.22
www.reuters.com - May 11 at 10:34 PM
finance.yahoo.com logoEdited Transcript of EARS earnings conference call or presentation 11-May-17 12:00pm GMT
finance.yahoo.com - May 11 at 10:34 PM
finance.yahoo.com logoAuris Medical Provides Business Update and Reports First Quarter 2017 Financial Results
finance.yahoo.com - May 11 at 8:57 AM
finance.yahoo.com logoInvestor Network: Auris Medical Holding AG to Host Earnings Call
finance.yahoo.com - May 11 at 8:57 AM
finance.yahoo.com logoAuris reports 1Q loss
finance.yahoo.com - May 11 at 8:57 AM
feeds.benzinga.com logoAuris Medical Provides Business Update and Reports First Quarter 2017 Financial Results
feeds.benzinga.com - May 11 at 6:43 AM
nasdaq.com logoAuris Medical Reports Key Results from Keyzilen® AMPACT1 Open ... - Nasdaq
www.nasdaq.com - May 10 at 6:40 AM
globenewswire.com logoAuris Medical Reports Key Results from Keyzilen® AMPACT1 Open ... - GlobeNewswire (press release)
globenewswire.com - May 9 at 4:50 PM
finance.yahoo.com logoAuris Medical Reports Key Results from Keyzilen® AMPACT1 Open-Label Extension Study
finance.yahoo.com - May 9 at 4:50 PM
americanbankingnews.com logoAuris Medical Holding AG (EARS) Scheduled to Post Earnings on Thursday
www.americanbankingnews.com - May 9 at 7:02 AM
americanbankingnews.com logoAuris Medical Holding AG (EARS) Given Consensus Recommendation of "Buy" by Brokerages
www.americanbankingnews.com - May 8 at 4:36 PM
nasdaq.com logoAuris Medical to Announce First Quarter 2017 Financial Results and Host Conference Call on May 11,
www.nasdaq.com - May 5 at 3:03 AM
globenewswire.com logoAuris Medical to Announce First Quarter 2017 Financial Results and Host Conference Call on May 11, 2017 - GlobeNewswire (press release)
www.globenewswire.com - May 4 at 10:01 AM
finance.yahoo.com logoAuris Medical to Announce First Quarter 2017 Financial Results and Host Conference Call on May 11, 2017
finance.yahoo.com - May 4 at 10:01 AM
americanbankingnews.com logoAuris Medical Holding AG (EARS) Given News Impact Score of -0.03
www.americanbankingnews.com - May 4 at 9:44 AM
americanbankingnews.com logo Brokerages Expect Auris Medical Holding AG (EARS) Will Announce Earnings of -$0.10 Per Share
www.americanbankingnews.com - May 3 at 5:58 PM
americanbankingnews.com logoAuris Medical Holding AG (EARS) Given Daily News Impact Rating of 0.05
www.americanbankingnews.com - May 1 at 6:30 PM
seekingalpha.com logoAuris Medical Company Overview
seekingalpha.com - April 28 at 5:55 PM
americanbankingnews.com logoAuris Medical Holding AG (EARS) Earning Somewhat Critical Press Coverage, Study Shows
www.americanbankingnews.com - April 28 at 12:38 PM
streetinsider.com logoAuris Medical Holding (EARS) Announces Results from Keyzilen AMPACT2 Open-Label Extension Study
www.streetinsider.com - April 24 at 4:44 PM
globenewswire.com logoAuris Medical Reports Key Results from Keyzilen® AMPACT2 Open-Label Extension Study - GlobeNewswire (press release)
globenewswire.com - April 24 at 8:45 AM
feeds.benzinga.com logoAuris Medical Reports Key Results from Keyzilen® AMPACT2 Open-Label Extension Study
feeds.benzinga.com - April 24 at 8:28 AM
americanbankingnews.com logoAuris Medical Holding AG (EARS) Receives News Impact Rating of 0.07
www.americanbankingnews.com - April 21 at 1:23 PM
reuters.com logoTwo-horse race: Auris, Otonomy seek FDA nod for inner-ear therapies - Reuters
www.reuters.com - April 21 at 12:09 PM
finance.yahoo.com logoTwo-horse race: Auris, Otonomy seek FDA nod for inner-ear therapies
finance.yahoo.com - April 20 at 5:00 PM
americanbankingnews.com logoAuris Medical Holding AG (EARS) Getting Very Positive Media Coverage, Study Shows
www.americanbankingnews.com - April 18 at 10:18 AM
americanbankingnews.com logoAuris Medical Holding AG (EARS) Short Interest Update
www.americanbankingnews.com - April 15 at 7:08 AM
americanbankingnews.com logoAuris Medical Holding AG (EARS) Getting Somewhat Positive Press Coverage, AlphaOne Reports
www.americanbankingnews.com - April 14 at 8:46 PM
americanbankingnews.com logoAuris Medical Holding AG (EARS) Receives Consensus Rating of "Buy" from Analysts
www.americanbankingnews.com - April 13 at 1:20 PM
americanbankingnews.com logoRoth Capital Begins Coverage on Auris Medical Holding AG (EARS)
www.americanbankingnews.com - April 13 at 1:00 PM
seekingalpha.com logoPremarket analyst action - healthcare
seekingalpha.com - April 13 at 11:33 AM
americanbankingnews.com logoZacks: Auris Medical Holding AG (EARS) Receives Consensus Rating of "Buy" from Analysts
www.americanbankingnews.com - April 3 at 11:39 PM
streetinsider.com logoAuris Medical Holding (EARS) Receives Nasdaq Notice of Bid Price Deficiency
www.streetinsider.com - April 1 at 5:00 PM
streetinsider.com logoAuris Medical Holding (EARS) Receives Nasdaq Notice of Bid Price Deficiency - StreetInsider.com
www.streetinsider.com - April 1 at 8:34 AM
finance.yahoo.com logoAuris Medical Announces Receipt of Nasdaq Notice of Bid Price Deficiency
finance.yahoo.com - March 31 at 4:57 PM
americanbankingnews.com logoNeedham & Company LLC Cuts Auris Medical Holding AG (EARS) Price Target to $4.00
www.americanbankingnews.com - March 20 at 12:34 PM
finance.yahoo.com logoAURIS MEDICAL HOLDING AG Financials
finance.yahoo.com - March 17 at 5:10 PM
reuters.com logoBRIEF-Auris Medical expects 2017 operating expenses will be in range of chf 28 to 32 mln
www.reuters.com - March 15 at 10:19 PM
finance.yahoo.com logoEdited Transcript of EARS earnings conference call or presentation 14-Mar-17 12:00pm GMT
finance.yahoo.com - March 15 at 6:56 AM
americanbankingnews.com logoAuris Medical Holding AG (EARS) PT Lowered to $4.00
www.americanbankingnews.com - March 14 at 2:54 PM
streetinsider.com logoAuris Medical Holding (EARS) Posts FY16 Loss of $0.89/Share, Provides Business Update
www.streetinsider.com - March 14 at 12:58 PM
finance.yahoo.com logoAuris Medical Provides Business Update and Reports Full Year 2016 Financial Results
finance.yahoo.com - March 14 at 12:58 PM
biz.yahoo.com logoQ4 2016 Auris Medical Holding AG Earnings Release - Before Market Open
biz.yahoo.com - March 14 at 12:58 PM
feeds.benzinga.com logoAuris Medical Provides Business Update and Reports Full Year 2016 Financial Results
feeds.benzinga.com - March 14 at 6:57 AM
finance.yahoo.com logoAuris Medical to Present at the 29th Annual Roth Conference on March 14
finance.yahoo.com - March 8 at 5:39 PM
globenewswire.com logoAuris Medical to Announce Full Year 2016 Financial Results and Host Conference Call on March 14 - GlobeNewswire (press release)
globenewswire.com - March 7 at 4:45 PM
finance.yahoo.com logoAuris Medical to Announce Full Year 2016 Financial Results and Host Conference Call on March 14
finance.yahoo.com - March 7 at 11:54 AM

Social

Chart

Auris Medical Holding AG (EARS) Chart for Wednesday, May, 24, 2017

This page was last updated on 5/24/2017 by MarketBeat.com Staff